Renal excretion of some prostate-specific membrane antigen (PSMA) ligands and consequently
increased bladder activity can obscure locally relapsing prostate cancer lesions in
PSMA PET/CT. Furthermore, additional late imaging in PSMA PET/CT provides a useful
method to clarify uncertain findings. The aim of this retrospective study was to investigate
a modified imaging protocol combining late additional imaging with hydration and forced
diuresis in individuals undergoing additional late scanning for uncertain lesions
or low prostate-specific antigen. Methods: We compared an older protocol with a newer
one. In the old protocol, patients undergoing 68Ga-PSMA-11 PET/CT were examined at
90 min after injection, with 1 L of oral hydration beginning at 30 min after injection
and 20 mg of furosemide given intravenously at 1 h after injection, followed by additional
late imaging at 2.5 h after injection without further preparation. In the new protocol,
a second group received the same procedure as before, with an additional 0.5 L of
oral hydration and 10 mg of furosemide intravenously 30 min before the late imaging.
We examined 132 patients (76 with the old protocol and 56 with the new one) with respect
to urinary bladder activity (SUVmean), prostate cancer lesion uptake (SUVmax), and
lesion contrast (ratio of tumor SUVmax to bladder SUVmean for local relapses and ratio
of tumor SUVmax to gluteal-muscle SUVmean for nonlocal prostate cancer lesions). Results:
Bladder activity was significantly greater for the old protocol in the late scans
than for the new protocol (ratio of bladder activity at 2.5 h to bladder activity
at 1.5 h, 2.33 ± 1.17 vs. 1.37 ± 0.50, P < 0.0001). Increased tumor SUVmax and contrast
were seen at 2.5 h compared with 1.5 h (P < 0.0001 for old protocol; P = 0.02 for
new protocol). Increased bladder activity for the old protocol resulted in decreased
lesion-to-bladder contrast, which was not the case for the new protocol. Tumor-to-background
ratios increased at late imaging for both protocols, but the increase was significantly
lower for the new protocol. For the old protocol, comparing the 1.5-h to the 2.5-h
acquisitions, 4 lesions in 4 patients (4/76 = 5.2% of the cohort) were visible at
the postdiuresis 1.5-h acquisition but not at 2.5 h, having been obscured as a result
of the higher bladder activity. In the new protocol, 2 of 56 (3.6%) patients had lesions
visible only at late imaging, and 2 patients had lesions that could be better discriminated
at late imaging. Conclusion: Although the combination of diuretics and hydration can
be a useful method to increase the visualization and detectability of locally recurrent
prostate cancer in standard 68Ga-PSMA-11 PET/CT, their effects do not sufficiently
continue into additional late imaging. Additional diuresis and hydration are recommended
to improve the visibility, detection, and diagnostic certainty of local recurrences.